Get The Free Sample Complete
SWOT & PESTLE Analysis Report
This report is shared in order to give you an idea of what the complete SWOT & PESTLE analysis report will cover after purchase. We invest deep in order to bring you insightful research which can add tangible value to your business or academic goals. We also guarantee that you cannot find matched quality at such competitive and economic pricing.
Get Your Free Summary Copy of the
SWOT & PESTLE Analysis Report
Get the summary SWOT & report delivered straight to your email inbox for free.
Our insightful and holistic reports have helped corporate,academia and researchers to take their research forward. Like us on Facebook to stay updated with the latest published SWOT & PESTLE Report.

Bristol-Myers Squibb (BMS) SWOT & PESTLE Analysis

ID : 52385653| Feb 2019

COMPANY PROFILE -Bristol-Myers Squibb (BMS)

Business Sector :Pharmaceuticals

Operating Geography :United States, Global

About Bristol-Myers Squibb (BMS) :

Bristol-Myers Squibb (BMS) is an American pharmaceutical company, headquartered in New York City. Their products are sold worldwide (U.S. being the biggest market, contributing 55% to overall revenue) and manufactured in the U.S., Puerto Rico and in five foreign countries. BMS was formed by the 1989 merger of Squibb (founded in 1858 in Brooklyn) and Bristol-Myers (founded in 1887 in Clinton, New York). Their Products can be categorized in the following major therapeutic classes: oncology; cardiovascular; immune-science; and virology, including HIV infection.

Its mission statement states ‘At Bristol-Myers Squibb, our mission is to discover, develop and deliver innovative medicines that help patients prevail over serious diseases.’

Bristol-Myers Squibb (BMS) Revenue :

$20.77 billion – FY ending Dec 2017

$19.43 billion – FY ending Dec 2016

Competitive Analysis of Bristol-Myers Squibb (BMS)

The SWOT analysis for Bristol-Myers Squibb is presented below:
1. Innovation – New Product Development
2. Strong focus on R&D
3. Strong brand portfolio
4. High credit rating, low borrowing cost
5. Complimentary alliances for vertical integration
6. Strategic investment in sales & marketing
1. Revenue dependence on few prioritized brands
2. Weak presence in biologics segment
1. Growing cancer immunotherapy market
2. Increasing globalization in Pharma industry, opening of new markets through trade agreements
3. Leverage advance digital technologies to transform healthcare
1. Increasing competition from generic drugs manufacturers
2. Changes in U.S. or foreign laws and regulations
3. Adverse changes in U.S., global, regional or local economic conditions
SWOT & PESTLE (combined)
Complete Report
USD 12.53
Great quality, Affordable pricing.
Safe and secure payments

Detailed SWOT Analysis of Bristol-Myers Squibb (BMS)



This section is available only in the 'Complete Report' on purchase.


1. Revenue dependence on few prioritized brands: If we analyze product wise sales of BMS we can see that top selling prioritized drugs (namely Opdivo, Eliquis, Orencia, Sprycel,Yervoy and Baraclude) constituted around 80% of revenue in year 2017. Revenue share of products shows that the company depends heavily on its key products and lacks differentiation in product portfolio.

2. Weak presence in biologics segment: Biologics have revolutionized the treatment of many serious and chronic illnesses and many companies are investing heavily considering the future potential including BMS, however if we look at the top 10 biologics brand, not a single product is from BMS.


This section is available only in the 'Complete Report' on purchase.


1. Increasing competition from generic drug manufacturers: One of the biggest competitive challenges that BMS face is from generic pharmaceutical manufacturers. Generic manufacturers typically utilize the expired patents of research pharmaceutical companies and thus they are able to keep their R&D investments significantly low and therefore can price their products significantly lower than branded products. Upon the expiration or loss of market exclusivity on a product, BMS can lose the major portion of revenues of that product in a very short period of time.

2. Changes in U.S. or foreign laws and regulations: In many countries determination of pricing and reimbursement for pharmaceutical product is subject to government control. In most EU countries, for example, the government regulates pricing of a new product at launch often through direct price controls, international price comparisons, controlling profits and/or reference pricing. In recent years, Italy, for example, has imposed mandatory price decreases.

SWOT & PESTLE (combined)
Complete Report
USD 12.53
Great quality, Affordable pricing.
Safe and secure payments

Check out analysis of other relevant companies

References used in Bristol-Myers Squibb (BMS) Analysis Report

1. Bristol-Myers Squibb Annual Report 2016:

2. Bristol-Myers Squibb Company Analysis

3. BMS areas of focus

4. Most Innovative Companies

5. Reshaping Bristol-Myers-Squibb

6. BMS list of products

7. Product sales summary

8. Top 10 Biologic Drugs in the United States

9. The top 15 spenders in the global drug R&D business: 2017

10. From vision to decision: Pharma 2020

11. Awards and achievements

12. Cancer immunotherapy market race

13. World Population Prospects: The 2017 Revision; Gloabl Pharma Prospects

14. Environmental Performance

15. Sustainability 2020 Goals

Copyrights and Disclaimer

Bristol-Myers Squibb (BMS) SWOT and PESTLE analysis has been conducted by Sachin Mishra and reviewed by senior analysts from Barakaat Consulting.

Copyright of Bristol-Myers Squibb (BMS) SWOT and PESTLE Analysis is the property of Barakaat Consulting. Please refer to the Terms and Conditions and Disclaimer for usage guidelines.

Bristol-Myers Squibb (BMS) SWOT & PESTLE Analysis
Price : USD 12.53